Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2157-2165

  Rand, Robert W ^a   Kreitman, Robert J ^b   Patronas, Nicholas ^c   Varricchio, Frederick ^d   Pastan, Ira ^b   Puri, Raj K ^c,d  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CHIMERIC PROTEIN; GADOLINIUM; HYBRID PROTEIN; LOMUSTINE; PSEUDOMONAS EXOTOXIN; RECOMBINANT INTERLEUKIN 4; VINCRISTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CRANIOTOMY; DRUG SAFETY; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; INTRACRANIAL HYPERTENSION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STEREOTAXIC SURGERY; TUMOR NECROSIS;

ADULT; AGED; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; EXOTOXINS; FEMALE; GADOLINIUM; GLIOMA; HUMANS; IMMUNOTOXINS; INTERLEUKIN-4; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NECROSIS; PSEUDOMONAS; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034047780     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Salcman, M. Epidemiology and factors affecting survival. In: M. L. J. Apuzzo (ed.). Malignant Cerebral Glioma. Park Ridge, IL: American Association of Neurological Surgeons, 1980.
2. Frankel, S. A., and German, W. J. Glioblastoma multiforme (review of 219 cases with regard to natural history, pathology, diagnostic methods and treatment). J. Neurosurg., 15: 489-503, 1985.
3. Walker, A. E., Robins, M., and Weinfeld, F. D. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology, 35: 219-226, 1985.
4. Hall, W. A., Djalilian, H. R., Sperduto, P. W., Cho, K. H., Gerbi, B. J., Gibbons, J., Rohr, M., and Clark, M. B. Stereotactic radiosurgery for recurrent malignant gliomas. J. Clin. Oncol., 13: 1642-1648, 1995.
5. Walker, M. D., Alexander, E., Hunt, W. E., MacCarthy, C. S., Mahaley, M. S., Jr., Mealey, J., Jr., Norrell, H. A., Owens, A., Ranshoff, J., Wilson, C. B., Gehan, E. A., and Strike, T. A. Evaluation of BCNU and/or radiotherapy in treatment of anaplastic gliomas. J Neurosurg., 49: 333-343, 1978.
6. Levin, V. A., Gutin, P. H., and Leibel, S. Neoplasms of the central nervous systems. In: V. T. De Vita, S. Hellman, and S. A. Roseberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 5, pp. 2041-2050. Philadelphia: J. B. Lippincott, 1997.
7. Mehaley, M. S., Jr., Mettlin, C., Natarajan, N., Laws, E. R., Jr., and Peace, B. B. National survey of patterns of care for brain-tumor patients. J. Neurosurg., 71: 826-836, 1989.
8. Fine, H. A. Chemotherapy in the treatment of malignant astrocytomas in adults. In: P. M. Black and L. Lampson (eds.), Astrocytomas. Boston: Blackwell (in press).
9. Puri, R. K., Leland, P., Kreitman, R. J., and Pastan, I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the cytotoxic effect of IL-4 Pseudomonas exotoxin chimeric protein. Int. J. Cancer., 58: 574-581, 1994.
10. Puri, R. K., Hoon, S. B., Leland, P., Snoy, P., Rand, R. W., Pastan, I., and Kreitman R. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of a malignant astrocytoma. Cancer Res., 56: 5631-5637, 1996.
11. Puri, R. K., Debinski, W., Obiri, N., Kreitman, R., and Pastan, I. Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein comprised of human interleukin-4 and Pseudomonas exotoxin. Cell. Immunol., 154: 369-379, 1994.
12. Puri, R. K., Mehrotra, P. T., Leland, L., Kreitman, R., Siegel, J. P., and Pastan, I. Chimeric protein comprised of IL-4 and Pseudomonas exotoxin (IL4-PE4E) is cytotoxic for activated human lymphocytes. J. Immunol., 152: 3693-3700, 1994.
13. Kreitman, R. J., Puri, R. K., and Pastan, I. A circularly permutated recombinant interleukin-4 toxin with increased activity. Proc. Natl. Acad. Sci. USA, 91: 6889-6893, 1994.
14. c chain in RCC cells does not improve sensitivity. Cell. Immunol., 171: 80-86, 1996.
15. Kreitman, R. J., Puri, R. K., and Pastan, I. Increased antitumor activity of a circularly permuted Interleukin 4-toxin in mice with Interleukin 4 receptor-bearing human carcinoma. Cancer Res., 55: 3357-3363, 1995.
16. Husain, S. R., Behari, N., Kreitman, R. J., Pastan, I., and Puri, R. K. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy. Cancer Res., 58: 3649-3653, 1998.
17. Lieberman, D. M., Laske, D. W., Morrison, P. F., Bankiewicz, K. S., and Oldfield, E. H. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J. Neurosurg., 82: 1021-1029, 1995.
18. Morrison, P. F., Laske, D. W., Bobo, H., Oldfield, E. H., and Dedrick, R. L. High-flow microinfusion: tissue penetration and pharmacodynamics. Am. J. Physiol., 266; R262-R305, 1994.
19. Laske, D. W., Ilercil, O., Akbasak, A., Youle, R. J., and Oldfield, E. H. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J. Neurosurg., 80: 520-526, 1994.
20. Laske, D. W., Youle, R. J., and Oldfield, E. H. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat. Med., 3: 1362-1368, 1997.
21. Puri, R. K. Structure and function of interleukin 4 and its receptors. In: R. Kurzrock and M. Talpaz (eds.), Cytokines: Interleukins and Their Receptors, pp. 143-185. Norwell, MA: Kluwer Academic Publishers, 1995.
22. Pastan, I., Chaudhary, V. K., and FitzGerald, D. J. Recombinant toxins as novel therapeutic agents. Annu. Rev. Biochem., 61: 331-354, 1992.
23. Keppler-Hafkemeyer, A., Brinkmann, U., and Pastan, I. Role of caspases in immunotoxin-induced apoptosis of cancer cells. Biochemistry, 37; 16934-16942, 1998.
24. Massicotte, E. M., and Del Bigio, M. R. Human arachnoid villi response to subarachnoid hemorrhage: possible relationship to chronic hydrocephalus. J. Neurosurg., 91: 60-84, 1999.
25. Hall, W. A., and Fodstad, A. E. Immunotoxins and central nervous system neoplasia. J. Neurosurg., 76: 1-2, 1992.
26. Frankel, A. E., FitzGerald, D., Siegall, C., and Press, O. W. Advances in immunotoxin biology and therapy: a summary of the Fourth International Symposium on Immunotoxins. Cancer Res., 56: 926-932, 1996.
27. Youle, R. J. Immunotoxins for central nervous system malignancy. Semin. Cancer Biol., 7: 65-70, 1996.
28. Leland, P., Taguchi, J., Husain, S. R., Kreitman, R. J., Pastan I., and Puri, R. K. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo. Mol. Med., in press, 2000.
29. Husain, S. R., Kreitman, R. J., Pastan, I., and Puri, R. K. Interleukin-4 receptor directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat. Med., 5: 817-822, 1999.
30. Pastan, I., and FitzGerald, D. Recombinant toxins for cancer treatment. Science (Washington DC), 254: 1173-1177, 1991.
31. Pai, L. H., Wittes, R., Setser, A., Willingham, M. C., and Pastan, I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pxeudomonas exotoxin. Nat. Med., 2: 350-353, 1996.
32. Kreitman, R. J., Wilson, W. H., White, J. D., Stetler-Stevenson, M., Jaffe, E., Waldman, T. A., and Pastan, I. Phase I trial of recombinant immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol., in press, 2000.
33. Kreitman, R. J., Wilson, W. H., Robbins, D., Margulis, I., Stetler-Stevenson, M., Waldman, T. A., and Pastan, I. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood, 94: 3340-3348, 1999.
34. Hesketh, P., Caguioa, P., Koh, H., Dewey, H., Facada, A., McCaffrey, R., Parker, K., Nylen, P., and Woodworth, T. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. Blood, 11: 1682-1690, 1993.
35. Amlot, P. L., Stone, M. J., Cunnigham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., Ghetie, V., Ramilo, O., Thorpe, P. E., Uhr, J. W., and Vitetta, E. S. A Phase I study of an anti-CD22-deglycosylated Ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 82: 2624-2633, 1993.
36. Stone, M. J., Sausville, E. A., Fay, J. W., Headlee, D., Collins, R. H., Figg, W. D., Stetler-Stevenson, M., Jain, V., Jaffe, E. S., Solomon, D., Lush, R. M., Senderowicz, A., Ghetie, V., Schindler, J., Uhr, J. W., and Vitetta, E. S. A Phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood, 88: 1188-1197, 1996.